398 related articles for article (PubMed ID: 30015770)
1. BILATERAL INTRAVITREAL 0.19-MG FLUOCINOLONE ACETONIDE IMPLANT FOR PERSISTENT NONDIABETIC CYSTOID MACULAR EDEMA AFTER VITRECTOMY.
Ong SS; Walter SD; Chen X; Thomas AS; Finn AP; Fekrat S
Retin Cases Brief Rep; 2021 May; 15(3):261-265. PubMed ID: 30015770
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal fluocinolone acetonide implant for the treatment of persistent post-surgical cystoid macular edema in vitrectomized eyes.
Miguel-Escuder L; Olate-Pérez Á; Sala-Puigdoners A; Moll-Udina A; Figueras-Roca M; Navarro-Angulo MJ; Adán A; Pelegrín L
Eur J Ophthalmol; 2023 Jan; 33(1):NP23-NP27. PubMed ID: 34836464
[TBL] [Abstract][Full Text] [Related]
3. Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency.
Adams OE; Schechet SA; Hariprasad SM
Eur J Ophthalmol; 2021 Mar; 31(2):612-619. PubMed ID: 31964171
[TBL] [Abstract][Full Text] [Related]
4. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
[TBL] [Abstract][Full Text] [Related]
5. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN
Panos GD; Arruti N; Patra S
Eur J Ophthalmol; 2021 Mar; 31(2):620-629. PubMed ID: 31906704
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal Sustained-Release Steroid Implants for the Treatment of Macular Edema following Surgical Removal of Epiretinal Membranes.
Hattenbach LO; Springer-Wanner C; Hoerauf H; Callizo J; Jungmann S; Brauns T; Fulle G; Eichel S; Koss MJ; Kuhli-Hattenbach C
Ophthalmologica; 2017; 237(4):232-237. PubMed ID: 28463851
[TBL] [Abstract][Full Text] [Related]
7. Fluocinolone acetonide implantable device for diabetic retinopathy.
Schwartz SG; Flynn HW
Curr Pharm Biotechnol; 2011 Mar; 12(3):347-51. PubMed ID: 20939799
[TBL] [Abstract][Full Text] [Related]
8. Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine-Gass Syndrome.
Marques JH; Abreu AC; Silva N; Meireles A; Pessoa B; Melo Beirão J
Int Med Case Rep J; 2021; 14():127-132. PubMed ID: 33664598
[TBL] [Abstract][Full Text] [Related]
9. Fluocinolone acetonide for the treatment of diabetic macular edema.
Veritti D; Sarao V; Diplotti L; Samassa F; Lanzetta P
Expert Opin Pharmacother; 2017 Oct; 18(14):1507-1516. PubMed ID: 28764565
[TBL] [Abstract][Full Text] [Related]
10. Fluocinolone acetonide intravitreal implant as a therapeutic option for severe Sjögren's syndrome-related keratopathy: a case report.
Wasielica-Poslednik J; Pfeiffer N; Gericke A
J Med Case Rep; 2019 Jan; 13(1):21. PubMed ID: 30674351
[TBL] [Abstract][Full Text] [Related]
11. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
Syed YY
Drugs; 2017 Apr; 77(5):575-583. PubMed ID: 28283896
[TBL] [Abstract][Full Text] [Related]
12. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
Holden SE; Kapik B; Beiderbeck AB; Currie CJ
Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
[No Abstract] [Full Text] [Related]
13. Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema.
Sanford M
Drugs; 2013 Feb; 73(2):187-93. PubMed ID: 23335133
[TBL] [Abstract][Full Text] [Related]
14. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
[TBL] [Abstract][Full Text] [Related]
15. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.
Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C
Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148
[TBL] [Abstract][Full Text] [Related]
16. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy.
Meireles A; Goldsmith C; El-Ghrably I; Erginay A; Habib M; Pessoa B; Coelho J; Patel T; Tadayoni R; Massin P; Atorf J; Augustin AJ
Eye (Lond); 2017 May; 31(5):684-690. PubMed ID: 28085139
[TBL] [Abstract][Full Text] [Related]
18. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
Soubrane G; Behar-Cohen F
J Fr Ophtalmol; 2015 Feb; 38(2):159-67. PubMed ID: 25601517
[TBL] [Abstract][Full Text] [Related]
19. Fluocinolone acetonide intravitreal implant (Retisert
Leinonen S; Immonen I; Kotaniemi K
Acta Ophthalmol; 2018 Sep; 96(6):648-651. PubMed ID: 29655222
[TBL] [Abstract][Full Text] [Related]
20. Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study.
Deuchler SK; Schubert R; Singh P; Chedid A; Kenikstul N; Scott J; Kohnen T; Ackermann H; Koch F
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2537-2547. PubMed ID: 35239010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
